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The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune),
CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing datasets of
primary tumor samples mainly from early stage colon cancer patients. Consequently, rectal tumors and stage IV tumors
(possibly reflective of more aggressive disease) were underrepresented, and no chemo- and/or radiotherapy pretreated samples
or metastatic lesions were included. In view of their possible effect on gene expression and consequently subtype classification,
sample source and treatments received by the patients before collection must be carefully considered when applying the
classifier to new datasets. Recently, several correlative analyses of clinical trials demonstrated the applicability of this
classification to the metastatic setting, confirmed the prognostic value of CMS subtypes after relapse and hinted at differential
sensitivity to treatments. Here, we discuss why contexts and equivocal factors need to be taken into account when analyzing
clinical trial data, including potential selection biases, type of platform, and type of algorithm used for subtype prediction. This
perspective article facilitates both our clinical and research understanding of the application of this classifier to expedite
subtype-based clinical trials.
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Introduction
Colorectal cancer (CRC) is highly heterogeneous at the genomic
and transcriptomic levels [1]. Only a few genomic biomarkers,
namely microsatellite instability (MSI) and extended RAS and
BRAF mutational status, are routinely used for prognostication
and treatment prediction in clinical practice [2, 3]. Although sev-
eral multi-gene assays such as Oncotype DX, ColoPrint and
ColDX have demonstrated independent prognostic value in
early-stage CRC, their use is currently not recommended by
international guidelines due to unclear clinical utility over cur-
rent risk stratification factors and due to the lack of value in pre-
dicting treatment benefit [3]. Whether gene expression
signatures add clinically relevant information to existing clinical
subgroups in early or advanced stages is controversial.
Using a network-based approach to match six distinct classi-
fiers, we, along with other members of the CRC Subtyping
Consortium (CRCSC), identified four robust consensus
molecular subtypes (CMS): CMS1, enriched for inflammatory/
immune genes; CMS2, canonical; CMS3, metabolic; and CMS4,
mesenchymal [4]. Stage-independent prognostic value and sig-
nificant associations with multiple clinical and biological features
were demonstrated. These data were subsequently validated in
multiple retrospective analyses of prospectively collected clinical
trial samples [5–8]. Our group also demonstrated the potential
predictive value of molecular subtypes with respect to the
FOLFIRI (a combination of 5-flurouracil, leucovorin and irinote-
can) chemotherapy regimen and the anti-epidermal growth fac-
tor receptor (EGFR)-targeted agent cetuximab using our
previously published subtype classifier (CRCAssigner) that is
now reconciled into the CMS subtypes [9]. Similar findings have
been described in cell lines and retrospective clinical cases by
others [10, 11]. Recently, the CMS subtypes were evaluated as in-
dependent prognostic factors of survival demonstrating consist-
ent results in correlative studies of phase III clinical trials
(Table 1); however, conflicting results were shown when tested as
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predictive factors of benefit from standard treatments in the
metastatic setting [5, 6]. Therefore, although the CMS subtypes
show real promise for patient stratification to guide new
biomarker-enriched clinical trials, a number of potential flaws
and challenges must be accounted for when retrospectively ana-
lyzing studies or designing new ones. An in-depth contextual
analysis of each study will help better understand the potential
clinical usefulness of this new classifier. In addition, a precise esti-
mate of biomarker prevalence in a specific clinical context is fun-
damental to define the target population and the distribution of
each subtype. Incorrect estimates may result in unsuccessful
screening efforts, wasted resources, and possibly even disadvan-
tage to patients. In this perspective article, we compare several
features of the original CRCSC population with recently pub-
lished data and publicly available datasets to highlight context-
specific subtype characteristics and important equivocal factors
to ultimately facilitate realistic application by the oncology
community.
Context 1: stage
In the CRCSC analysis, the biological characteristics of a subset of
the samples were analyzed. The vast majority (2715/2952; 92% of
samples with available information) were representative of early-
stage tumors at diagnosis, the remaining 8% of samples belong to
patients diagnosed with stage IV disease [4]. In developed coun-
tries, up to 30% of CRC patients have metastatic disease at diag-
nosis [12]. Therefore, this population is underrepresented in the
CRCSC analysis, and this factor must be taken into account when
applying the CMS classification to the metastatic setting. As an
example, CMS4 enrichment could be expected in advanced stage
tumors, and this requires consideration when designing a study
that prospectively selects or stratifies patients for particular sub-
types. Furthermore, it is plausible to consider reclassifying
advanced stage tumors de novo; new subtypes with activated ex-
pression pathways different from early stage tumors could be
identified.
With this limitation in mind, Figure 1A and B shows the differ-
ent CMS distributions in early and metastatic diseases at diagno-
sis from the original CRCSC dataset [4]. The poor prognostic
CMS4 group is enriched in the advanced setting, while the MSI-
enriched subtypes (predominantly CMS1 and partially CMS3)
are of low prevalence in the same setting [13].
Context 2: sample source
The CRCSC dataset was built from multiple datasets limited to
primary tumor samples. While the majority of samples were
from the colon, 15% of samples were rectal cancers, probably
because rectal tumors are more frequently treated with neoad-
juvant chemoradiotherapy so are not included in untreated
datasets. With this caveat, the proportion of the four subtypes
in the rectum was very different from those arising in the colon,
with only 12 samples (0.1% of total) belonging to CMS1
(Figure 1C). Conversely, the CMS1 subtype predominated in
tumors arising on the right-sided colon, in line with the high
prevalence of MSI and BRAF mutant tumors at this site. A simi-
lar variable distribution between the right and left colon (which
also included rectal samples) was further confirmed in a cor-
relative analysis of the FIRE-3 clinical study in the first-line set-
ting (6).
In another example, we demonstrated that CRC liver metasta-
ses could be classified according to CRC subtypes (developed
using primary tumor samples) by applying the CRCAssigner clas-
sifier to publicly available data from the Khambata-Ford dataset
[9, 14]. Here, we reclassified the same dataset using the CMS al-
gorithm [4]. In Figure 1D, we show the subtype distribution after
removal of 29% of the mixed/undetermined samples. While the
proportion of CMS2 is similar to that found in the left colon
(more frequently metastatic to the liver via the hepatic portal sys-
tem), CMS4 replaces the majority of CMS1 and CMS3. This is in
line with the peritoneum (instead of the liver) being the preferen-
tial site of relapse for BRAF-mutant (CMS1) and mucinous
tumors [15, 16]. Surprisingly, despite mutant KRAS being identi-
fied in 30 out of 80 patients, only 1 patient (2%) was classified as
CMS3. This depletion of CMS3 was recently confirmed in the
Oslo Co-Met trial molecular analysis, where, out of 44 samples,
no CMS3 tumors were identified but 68% were classified as
CMS2 [17]. Whether this is an effect of chemotherapy-induced
molecular changes in the liver or an intrinsic biological character-
istic of this subtype requires further analysis. Also, the tolerogenic
hepatic microenvironment maintained by immunosuppressive
cytokines interleukin-10 and transforming growth factor-b
(TGF-b) (CMS4-activated pathway) may potentially interfere
with subtype classification [4, 18]. Particular caution and further
validation studies are required especially in consideration of the
fact that the CMS subtypes were developed in the context of pri-
mary CRC and its applicability to metastatic tissues (including
those from liver, lung and peritoneum) has not yet been fully
established.
Lastly, in recent analyses, Dunne et al. demonstrated discord-
ant subtyping results from different tumor areas potentially due
to intra-patient heterogeneity and/or differentially expressed
stromal genes [19]. The same authors also questioned the robust-
ness of CMS subtypes in tissue biopsies, demonstrating a high
proportion of unclassified samples [20]. Intra-tumoral hetero-
geneity and sampling errors remain major open challenges. The
concordance between biopsies and resection specimens was not
considered in the original CRCSC dataset, highlighting again
how sample source needs to be carefully selected for each patient
for robust biomarker assessment.
Context 3: trial versus off-trial, first-line, and
chemorefractory settings
Only one dataset was related to a clinical trial (PETACC-3) in
the CRCSC study [4, 21]. Trial inclusion criteria usually exclude
patients with poor performance status, comorbidities, or heav-
ily symptomatic conditions, leading to underrepresentation of
patients with high disease burden and/or aggressive disease.
Conversely, retrospective series may often harbor hidden selec-
tion bias. Recently, at least three clinical trials in the first-line
setting with similar inclusion criteria (CALGB 80405, FIRE-3,
and AGITG MAX) were presented at international conferences
[5–7]. The CMS subtype distribution was consistent across
studies, and the proportion of subtypes in these trials from the
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metastatic setting was unexpectedly similar to the proportion of
early-stage subtypes in the CRCSC study, which was predomin-
antly off-trial. Surprisingly, nearly 80% of patients enrolled in
CALGB/SWOG 80405 had synchronous metastases at diagnosis
of the primary tumor. Given that some patients with stage IV
disease at diagnosis do not receive palliative primary tumor re-
section, the primary tumor sample may not have been available
for correlative studies. On the other hand, it is more likely that
the primary tumor was available for patients with early-stage
disease at diagnosis. Extensive publications of these analyses
including comparisons with the original study population are
eagerly awaited.
With respect to the chemorefractory setting, a preliminary ana-
lysis of CMS subtypes in a subset of patients (281/760; 37%)
enrolled in the CORRECT trial (regorafenib or placebo in
patients progressing to standard chemotherapy) was presented at
the ASCO Annual Meeting 2015 [22]. The predominant subtype
in this heavily pretreated population was CMS2 (50%) followed
by CMS4 (30%), while CMS1 and CMS3 were less represented at
9% and 11%, respectively. The relatively consistent subtype dis-
tribution in the first-line trials may explain the enrichment of
CMS2 and CMS4 over CMS3 and CMS1 after relapse in chemore-
fractory setting. Only patients with favorable tumor biology after
relapse are likely to reach the chemorefractory setting and main-
tain the fitness to be enrolled in clinical trials. Extensive analysis
of the full CORRECT or similar trials is warranted to address the
above hypothesis.
Context 4: enrichment by genomic or
clinical variables
As discussed above, there exist significant associations between
certain CMS subtypes and genomic, clinical, and pathological
variables, e.g. BRAF mutations, MSI, high histological grade, and
female gender with CMS1; RAS mutations with CMS3; and
advanced stages with CMS4. Therefore, subtypes distribution
may be modified by genomic or clinical selection criteria. In fact,
in the FIRE-3 analysis presented recently, different proportions
of CMS3 (11% in KRAS wild-type versus 25% in KRAS mutant
population) and CMS2 (41% versus 27%) were shown when
KRAS wild-type and mutant patients were analyzed separately.
Nevertheless, there was no significant difference in the propor-
tion of CMS1 and CMS4 [6]. Therefore, during the design of mo-
lecularly selected clinical trials, the variables used as inclusion
criteria may affect the subtype distribution. Hence, this factor
needs to be taken into consideration for clinical trial design.
Equivocal factor 1: different methods of
predicting CMS subtypes
Two different algorithms for CMS classification are available on-
line in the R ‘CMSclassifier’ package: one suitable for population-
based studies (random forest classifier) and one suitable for
single-sample prediction (Pearson correlation-based classifier,
A B
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Figure 1. (A and B) The proportions of each consensus molecular subtypes (CMS) colorectal cancer (CRC) subtype in (A) early stage (I–III) at
diagnosis, (B) stage IV at diagnosis, and (C) location of the tumors within the CRCSC dataset and (D) liver metastatic samples from the public-
ly available Khambata-Ford dataset [14].
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SSP) (4). The random forest classifier uses both different default
normalization and a different gene set to that of the SSP classifier.
Both provide two distinct subtyping results. First, the ‘predicted
CMS’ output includes the mixed/undetermined subtype along
with the four CMS subtypes. This classifier was used in reporting
the performance (such as sensitivity, specificity, and positive and
negative predictive values) described in the original publication.
The second is the ‘nearest CMS’ output, where each sample from
the undetermined/mixed group is forced into one of the four
CMS subtypes based on the dominant signature. Up to 13%
CRCSC samples were labeled as mixed/undetermined since they
did not classify into any of the four subtypes and did not repre-
sent a potentially distinct subtype. These may partially represent
low-quality samples; however, the majority of them are thought
to represent intra-tumoral heterogeneity, with more than one
subtype present in the same sample.
In order to understand whether the single-sample predictor
‘predicted’ or ‘nearest’ CMS subtype classifications affect prog-
nostication and prediction, we applied both to the well-used
Khambata-Ford dataset of metastatic patients treated with anti-
EGFR therapy [14]. Using the ‘predicted CMS’ subtyping, up to
29% of the samples (n¼ 23) remained mixed/undetermined
(Figure 2A), twice that of the CRCSC population (13% mixed/
undetermined). This may be attributed to the change in micro-
environment from the primary to secondary site (liver) or may
represent a technical artifact.
Conversely, using the ‘nearest CMS’, 52% (n¼ 12) of the pre-
viously mixed/undetermined 29% samples were classified as
CMS4. This subtype is enriched for mesenchymal and stromal
gene signatures, which may be derived from surrounding cells ra-
ther than being cancer specific. Further, 35% (n¼ 8) were classi-
fied as CMS2 (the most heterogeneous group). Interestingly, no
samples were relabeled as CMS3, again potentially due to liver
microenvironment or suggesting that the mixed/undetermined
group may include dominant CMS4 and CMS2 subtypes.
Recently, a new algorithm (CMScaller) optimized to apply the
CMS classification to pre-clinical models demonstrated 83% pre-
diction accuracy in primary CRC patient samples [23]. Based on
Khambata-Ford dataset
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Figure 2. (A and B) Pie charts distribution and Kaplan–Meier survival analyses for cetuximab progression-free survival in the Khambata-Ford
dataset [14] according to (A) predicted consensus molecular subtypes (CMS) subtype and (B) nearest CMS subtype. (C) The proportions of
each CMS in stage III colorectal cancer samples from the CRCSC dataset (top), the NSABP-C07 ancillary study (left bottom, modiﬁed from pre-
vious publication [15]), and the PETACC-8 ancillary study (right bottom, modiﬁed from previous publication [8]).
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cancer cell intrinsic signals, the authors did not yet recommend
its implementation in samples different than primary tumor re-
section specimens.
These examples highlight how the choice of which CMS pre-
dictor algorithm to use is crucial and the applicability of each al-
gorithm may be limited in certain contexts. While the majority
of publications have been based on single-sample predictor
‘predicted CMS’, quite a few use the ‘nearest CMS’ [24]. We be-
lieve that the use of predicted versus nearest CMS may have dif-
ferent consequences. For example, using the nearest CMS rather
than the predicted CMS loses the power to define significant
benefit from cetuximab treatment according to subtypes in the
Khambata-Ford dataset (Figure 2B). When mixed/undeter-
mined samples are forced into a CMS group, they cannot be dis-
tinguished from those with a definite CMS class and may
confound the result. This is likely to negatively impact on the
performance of the classifier and potentially mislead
investigators.
Equivocal factor 2: additional heterogeneity
leading to sub-classification
The proportion of canonical CMS2 subtype is the same in both
the early and advanced settings. Although not strongly associ-
ated with any of the common actionable genomic events in
CRC (such as RAS/BRAF mutations or MSI), this is possibly
the most heterogeneous gene expression subtype. In fact,
CMS2 includes two of our original CRCAssigner subtypes (en-
terocyte and Transit-Amplifying or TA) and three Marisa sub-
types (C1, C5, and C6) [4, 9, 25]. We and others demonstrated
diverse responses to anti-EGFR therapy in the TA subtype [9,
10]. More recently, in an intra-tumoral heterogeneity-based
analysis (in a small cohort of patient samples), we suggested
that the presence of TA sub-clones even in non-TA tumors is
associated with anti-EGFR therapy response [26]. Similarly,
potential differences in benefit between subtypes with and
without oxaliplatin-based adjuvant chemotherapy (survival
benefit in enterocyte versus the others) were suggested in an ex-
ploratory analysis of the NSABP-C07 trial; however, this was
not statistically significant in the validation cohort, although
similar trends were observed [27]. This heterogeneity was less
visible using the CMS classifier in the same cohort. Therefore,
it may be reasonable to subdivide the CMS2 to further under-
stand biological heterogeneity, stage distribution, and potential
personalized targets of this subtype. Similarly, in the PETACC-
8 subtype analysis, the authors demonstrated significantly dif-
ferent prognostic value when the CMS4 subtype was further
subdivided into CMS4-C4 (worse DFS and OS) and CMS4-not
C4, based on Marisa classification [8]. More recently, the same
authors demonstrated how 57% of 1779 profiled PETACC-8
samples showed intra-tumor heterogeneity assessed using an
in-silico deconvolution algorithm and this heterogeneity was
an independent predictor of relapse [28]. These examples high-
light how CMS subtypes define the overall profiles of major
CRC subgroups; however, even within each subtype, there may
be biological variability and important sub-subtypes with dis-
tinctive clinical/biological parameter that requires careful
consideration.
Equivocal factor 3: different platforms, gene
sets, and assays
The CRCSC analysis was originally performed using gene expres-
sion data derived from multiple platforms including Affymetrix
and Agilent microarrays, and RNA-sequencing [4]. In order to
accommodate a broader set of platforms, the consortium com-
bined classifiers trained on different platforms to classify samples
into CMS subtypes, thereby favoring the portability of the classi-
fier across platforms and maintaining high sensitivity, specificity,
and accuracy. Additionally, by virtue of good concordance of the
nCounter platform (NanoString Technologies, Seattle, WA,
USA) across multiple cancer types [29–31], several groups
including us have used this platform and a variable number of
genes to assay for subtypes [5, 8, 25, 32].
Initially, we selected a robust set of genes (n¼ 38) able to
classify samples into our CRCAssigner subtypes (originally
developed using 786 genes). We then optimized a low-cost
protocol for nCounter platform and validated the results using
matched RNAseq/microarray platform results [32]. After the
CRCSC collaboration, we further developed this assay to simul-
taneously classify samples into both CRCAssigner and CMS
subtypes [33]. We then demonstrated how the concordance be-
tween CRCAssigner and CMS classifiers using the nCounter
platform was maintained as per the multiplatform CRCSC
network.
Therefore, by virtue of the portability of the classifier initially
demonstrated by CRCSC and then validated by us, the type of
platform used is unlikely to affect the classification. However, the
number of genes in each assay and each gene’s contribution may
affect the subtype prediction and can explain differences between
studies.
The NSABP-C07 correlative study demonstrated a significant
recurrence-free survival advantage by adding oxaliplatin to
fluorouracil-leucovorin adjuvant therapy for the enterocyte sub-
type but not for the other subtypes [27]. In this study, the authors
used a custom nCounter platform assay (Colo-295), which was
designed before the publication of the CRCAssigner and CMS
gene expression subtypes. Up to 72 genes overlapped with our
original CRCAssigner-786 set. Similarly, the CMS subtypes
were defined based on 37 overlapping genes with the original 693
consensus genes. The CMS subtype distribution in this cohort
demonstrated enrichment for CMS1 (23%) and depletion of
CMS3 (8%) compared with the stage III CRCSC cohort
(Figure 2C) [4, 27].
A similar correlative phase III randomized trial in the same
setting (oxaliplatin, fluorouracil, and leucovorin with or with-
out cetuximab in patients with resected stage III colon cancer;
PETACC-8) was presented recently, with the extended publica-
tion awaited [8]. The NanoString assay was developed using
computational approaches and matched frozen and FFPE sam-
ples before being tested on a larger scale using the RNA
extracted from the PETACC-8 tissue biobank. Again, when
compared with the stage III CRCSC population, there was a sig-
nificantly lower proportion of the CMS3 subtype (only 4%) and
marked enrichment for CMS4 (45%). Similarly, when compar-
ing subtype distribution between the KRAS exon 2 wild-type
population in the correlative analyses of CALGB 80405 and
FIRE-3 first-line trials, the CMS3 NanoString subtype was
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present in 2% of samples (CALGB 80405) compared with 12%
of CMS3 microarray subtype (FIRE-3) [5, 6]. Therefore, the
proportion of CMS3 identified with different assays in these
cohorts requires further understanding. As previously men-
tioned, no definitive conclusions related to the role of the sub-
types in predicting benefit from bevacizumab or cetuximab can
be drawn from these two similar studies. While significant sur-
vival benefit was demonstrated in the CMS1-bevacizumab
group and in the CMS2-cetuximab group in the CALGB 80405,
no significant differences in the CMS1 group was shown and the
survival benefit associated with cetuximab seemed mainly
driven by the CMS4 group in the FIRE-3 [5, 6]. Given the previ-
ously discussed inter-platform consistency and the fact that the
same algorithm was used to predict the subtypes, the differences
in number and sets of genes analyzed may be a major contribu-
tor to inconsistent results.
Despite the potential clinical utility of CRCSC signatures for
outcome prediction or immune-targeted therapy development,
their clinical implementation is challenging due to lack of easy-
to-use and cost-effective assays suitable for paraffin tissues. As
previously indicated, different groups, including ours, are work-
ing on classifiers based on protein markers by immunohisto-
chemistry or gene expression signals using nCounter
VR
NanoString Technologies, for example, with overall accuracy
close to 90% when compared with the gold-standard CMS4 sig-
nature [32–35]. Technical validation has been proved for our
NanoString-based classifier, and clinical validation studies are
underway [32, 33]. In parallel, prospective molecularly stratified
clinical trials should be encouraged. One example is the
MoTriColor H2020 project, where mCRC patients with tumors
testing positive for a ‘TGF-b active’ or ‘MSI-like’ gene expression
signature in archived paraffin tissue are eligible to the combin-
ation of galunisertib (TGF-b receptor inhibitor) and capecitabine
or the combination of atezolizumab and bevacizumab, respect-
ively [36].
Conclusions and future directions
Molecular subtypes are context specific. The CMS subtypes
identify a further level of heterogeneity beyond standard gen-
omic biomarkers in CRC. To maximize their potential for per-
sonalized medicine, the contexts of application and equivocal
factors must be extensively considered to avoid misleading
results and premature rejection of a highly informative classifi-
cation system.
Acknowledgements
RMH/ICR authors acknowledge NHS funding for National
Institute for Health Research Royal Marsden and Institute of
Cancer Research Biomedical Research Centre. AS acknowledges
Cancer Research UK for PhD funding for EF through the ICR/
RMH.
Funding
None declared.
Disclosure
AS has ownership interest as a patent inventor for a patent entitled
‘Colorectal cancer classification with differential prognosis and
personalized therapeutic responses’ (patent number PCT/IB2013/
060416). AS—Research Funding—Bristol-Myers Squibb, Merck
KGaA and Pierre Fabre. RS - Advisory boards: Amgen, VCN-
BCN, Agendia, Guardant Health, Roche, Ferrer, Pfizer, Novartis,
Ipsen, Merck, Lilly, MSD; Speaker: Amgen, Pfizer, Novartis,
Merck, MSD, AZD, Celgene, Sace Medhealth; Consulting com-
pany: Sace Medhealth. All remaining authors have declared no
conflicts of interest.
References
1. Cancer Genome Atlas Network. Comprehensive molecular characteriza-
tion of human colon and rectal cancer. Nature 2012; 487(7407): 330.
2. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines
for the management of patients with metastatic colorectal cancer. Ann
Oncol 2016; 27(8): 1386–1422.
3. Benson AB, Venook AP, Al-Hawary MM et al. NCCN guidelines insights:
colon cancer, version 2.2018. J Natl Compr Canc Netw 2018; 16(4):
359–369.
4. Guinney J, Dienstmann R, Wang X et al. The consensus molecular sub-
types of colorectal cancer. Nat Med 2015; 21(11): 1350.
5. Lenz HJ, Ou FS, Venook AP et al. Impact of consensus molecular subtyp-
ing (CMS) on overall survival (OS) and progression free survival (PFS)
in patients (pts) with metastatic colorectal cancer (mCRC): analysis of
CALGB/SWOG 80405 (Alliance). JCO 2017; 35(Suppl 15): 3511–3511.
6. Stintzing S, Wirapati P, Lenz HJ et al. Consensus molecular subgroups
(CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus
cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. JCO
2017; 35(Suppl 15): 3510.
7. Mooi JK, Wirapati P, Asher R et al. The prognostic impact of consensus
molecular subtypes (CMS) and its predictive effects for bevacizumab
benefit in metastatic colorectal cancer: molecular analysis of the AGITG
MAX clinical trial. Ann Oncol 2018; 29(11): 2240–2246.
8. Marisa L, Ayadi M, Balogoun R et al. Clinical utility of colon cancer mo-
lecular subtypes: validation of two main colorectal molecular classifica-
tions on the PETACC-8 phase III trial cohort. JCO 2017; 35(Suppl 15):
3509.
9. Sadanandam A, Lyssiotis CA, Homicsko K et al. A colorectal cancer clas-
sification system that associates cellular phenotype and responses to ther-
apy. Nat Med 2013; 19(5): 619.
10. Medico E, Russo M, Picco G et al. The molecular landscape of colorectal
cancer cell lines unveils clinically actionable kinase targets. Nat Commun
2015; 6: 7002.
11. Del Rio M, Mollevi C, Bibeau F et al. Molecular subtypes of metastatic
colorectal cancer are associated with patient response to irinotecan-
based therapies. Eur J Cancer 2017; 76: 68–75.
12. Maringe C, Walters S, Rachet B et al. Stage at diagnosis and colorectal
cancer survival in six high-income countries: a population-based study
of patients diagnosed during 2000–2007. Acta Oncol 2013; 52(5):
919–932.
13. Fontana E, Poudel P, Nyamundanda G et al. 108PCharacterisation of
heterogeneity in microsatellite instable (MSI) tumours associated with
distinct cell types and immune phenotypes. Ann Oncol 2017; 28(Suppl
5): mdx363.024.
14. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin
and amphiregulin and K-ras mutation status predict disease control in
metastatic colorectal cancer patients treated with cetuximab. JCO 2007;
25(22): 3230–3237.
15. Tran B, Kopetz S, Tie J et al. Impact of BRAF mutation
and microsatellite instability on the pattern of metastatic spread and
prognosis in metastatic colorectal cancer. Cancer 2011; 117(20):
4623–4632.
Annals of Oncology Review
doi:10.1093/annonc/mdz052 | 7
16. Hugen N, Van de Velde CJ, De Wilt JH, Nagtegaal ID. Metastatic pattern
in colorectal cancer is strongly influenced by histological subtype. Ann
Oncol 2014; 25(3): 651–657.
17. Østrup O, Dagenborg VJ, Rødland EA et al. Molecular signatures reflect-
ing microenvironmental metabolism and chemotherapy-induced im-
munogenic cell death in colorectal liver metastases. Oncotarget 2017;
8(44): 76290.
18. Robinson MW, Harmon C, O’Farrelly C. Liver immunology and its
role in inflammation and homeostasis. Cell Mol Immunol 2016; 13(3):
267.
19. Dunne PD, McArt DG, Bradley CA et al. Challenging the cancer molecu-
lar stratification dogma: intratumoral heterogeneity undermines consen-
sus molecular subtypes and potential diagnostic value in colorectal
cancer. Clin Cancer Res 2016; 22(16): 4095–4104.
20. Alderdice M, Richman SD, Gollins S et al. Prospective patient stratifica-
tion into robust cancer cell intrinsic subtypes from colorectal cancer
biopsies. J Pathol 2018; 245(1): 19–28.
21. Van Cutsem E, Labianca R, Bodoky G et al. Randomized phase III trial
comparing biweekly infusional fluorouracil/leucovorin alone or with iri-
notecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
JCO 2009; 27(19): 3117–3125.
22. Teufel M, Schwenke S, Seidel H et al. Molecular subtypes and outcomes
in regorafenib-treated patients with metastatic colorectal cancer (mCRC)
enrolled in the CORRECT trial.
23. Eide PW, Bruun J, Lothe RA, Sveen A. CMScaller: an R package for con-
sensus molecular subtyping of colorectal cancer pre-clinical models. Sci
Rep 2017; 7(1): 16618.
24. Okita A, Takahashi S, Ouchi K et al. Consensus molecular subtypes clas-
sification of colorectal cancer as a predictive factor for chemotherapeutic
efficacy against metastatic colorectal cancer. Oncotarget 2018; 9(27):
18698.
25. Marisa L, de Reynie`s A, Duval A et al. Gene expression
classification of colon cancer into molecular subtypes:
characterization, validation, and prognostic value. PLoS Med 2013;
10(5): e1001453.
26. Fontana E, Nyamundanda G, Cunningham D et al. Molecular subtype
assay to reveal anti-EGFR response sub-clones in colorectal cancer
(CRC). JCO 2018; 36(Suppl 4): 658–658.
27. Song N, Pogue-Geile KL, Gavin PG et al. Clinical outcome from oxalipla-
tin treatment in stage II/III colon cancer according to intrinsic subtypes:
secondary analysis of NSABP C-07/NRG oncology randomized clinical
trial. JAMA Oncol 2016; 2(9): 1162–1169.
28. Laurent-Puig P, Marisa L, Ayadi M et al. Le Malicot K, Lepage C, Emile
JF, Salazar R, Aust D. 60PD Colon cancer molecular subtype intratu-
moral heterogeneity and its prognostic impact: an extensive molecular
analysis of the PETACC-8. Ann Oncol 2018; 29(Suppl 8): mdy269.058.
29. Chen X, Deane NG, Lewis KB et al. Comparison of nanostring
nCounter
VR
data on FFPE colon cancer samples and affymetrix micro-
array data on matched frozen tissues. PLoS One 2016; 11(5): e0153784.
30. Richard AC, Lyons PA, Peters JE et al. Comparison of gene expression
microarray data with count-based RNA measurements informs micro-
array interpretation. BMC Genomics 2014; 15(1): 649.
31. Prokopec SD, Watson JD, Waggott DM et al. Systematic evaluation of
medium-throughput mRNA abundance platforms. RNA 2013; 19(1):
51–62.
32. Ragulan C, Eason K, Nyamundanda G et al. A low-cost multiplex bio-
marker assay stratifies colorectal cancer patient samples into clinically-
relevant subtypes. bioRxiv 2017; 1: 174847.
33. Fontana E, Ragulan C, Eason K et al. 145O Validated nCounter platform
to stratify colorectal cancer (CRC) into Consensus Molecular Subtypes
(CMS) and CRCassigner subtypes in Asian population. Ann Oncol 2017;
28(Suppl 10): mdx659.003.
34. Trinh A, Trumpi K, Sousa EMF D et al. Practical and robust identifica-
tion of molecular subtypes in colorectal cancer by immunohistochemis-
try. Clin Cancer Res 2017; 23(2): 387–398.
35. Fontana E, Ragulan C, Cunningham D et al. Multiplatform assay to clas-
sify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC)
samples into molecular subtypes with mutational profiles. Ann Oncol
2017; 28(Suppl 5): mdx393.097.
36. http://www.motricolor.eu/ (31 May 2018, date last accessed)
Review Annals of Oncology
8 | Fontana et al.
